Olema Pharmaceuticals, Inc. (OLMA) · Oct 15, 2026 · Exec change

Olema Pharmaceuticals board resignation reshuffles key committees

Director resignation — Resignation effective October 14; committees reassigned October 15

Olema Pharmaceuticals disclosed a board resignation and immediate committee reassignment, with no stated operational disagreement or pipeline change.

Olema is a clinical-stage oncology company advancing palazestrant through pivotal Phase 3 breast-cancer trials while developing the earlier-stage OP-3136 program.

This is a governance reshuffle, not a change to the drug-development story. Dr. Gorjan Hrustanovic resigned from the board effective October 14 and left the Compensation and Science and Technology committees; the filing explicitly says the resignation was not due to a disagreement with the company. 〔0〕

Committee continuity is preserved. The board appointed Dr. Prakash Raman to both committees effective October 15, limiting the practical disruption to a seat change rather than a loss of oversight. 〔1〕

Bottom line: This is a routine executive-governance change with no disclosed impact on Olema’s clinical programs, strategy, or operating plans. It matters far less than the upcoming palazestrant data readouts that drive the company’s business story.

Original filing on SEC EDGAR

More Olema Pharmaceuticals, Inc. news

Olema Pharmaceuticals board resignation reshuffles key committees | OLMA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.